ZF, a Tier 1 automotive parts supplier, demonstrates its commitment to India’s industrial landscape with a robust manufacturing presence, exemplified by its recent record revenue of Rs. 10,000 crore solely from Indian operations. The company’s strategic focus on the Commercial Vehicle (CV) segment is underscored by the expansion of its Commercial Vehicle Solutions (CVS) Division, marked by the inauguration of the new Oragadam facility in Tamil Nadu on February 14, 2024.

Dr. Peter Laier, Member of the ZF Group Board of Management and Head of Commercial Vehicle Solutions and Industrial Technology, identifies this expansion as a significant milestone aligning with India’s growth trajectory and global imperatives to decarbonize CVs. Laier emphasizes ZF’s dedication to India’s industrial landscape, highlighting the country’s strategic importance and ZF’s increasing emphasis on design, engineering, and manufacturing capabilities in India to serve both domestic and global markets.

The Oragadam plant reflects ZF’s “Make in India for India and the World” approach, symbolizing the company’s commitment to local manufacturing excellence while meeting global demands. This multi-divisional facility is poised to contribute significantly to innovative solutions for safety, automation, connectivity, and electric mobility across commercial and passenger vehicles.

Laier reaffirms ZF’s global strategy and commitment to fostering innovation and growth in the Indian market, describing the Oragadam plant as a state-of-the-art facility aligned with ZF’s vision for sustainable, inclusive, and globally impactful manufacturing.

The inauguration of the Oragadam facility not only signifies ZF’s investment in India’s industrial growth but also underscores its dedication to advancing automotive technology, safety, and sustainability. As ZF continues to expand its manufacturing footprint and capabilities in India, it reinforces the country’s position as a key player in the global automotive industry while addressing evolving market needs and regulatory requirements



Leave a Reply

Your email address will not be published. Required fields are marked *

AlphaOmega Captcha Medica  –  What Do You See?


* Copy This Password *

* Type Or Paste Password Here *